Best Insurance Stocks To Invest In 2023

Cigna Corp. (CI Quick QuoteCI ) has announced an expansion of its plan offerings on the Affordable Care Act’s insurance exchanges, branching out into additional counties across three states for 2022.

The expansion brings the total number of states offering Cigna ACA plans to 13 in 313 counties.

Cigna is already one of the top providers of ACA plans, other companies being UnitedHealth Group Inc. (UNH Quick QuoteUNH ) , Centene Corp. (CNC Quick QuoteCNC ) , Molina Healthcare, Inc. (MOH Quick QuoteMOH ) among others.

Earlier this month, another health insurer Oscar Health announced that it will expand Obamacare to three new states in 2022.

In 2021, the ACA Marketplace entered its eighth year of operation. It became operational in 2014 as part of the Obamacare Care Act, which was enacted in March 2010 by the then President Barack Obama. The purpose of these online exchanges was to make health plan shopping more transparent and cost effective for Americans. Insurers offered their plans on these exchanges and had varied experiences with regard to profitability of the businesses conducted on these exchanges.

Best Insurance Stocks To Invest In 2023: Potlatch Corporation(PCH)

Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States. The Resource Management Division manages its timberlands, harvests timber, procures other wood fiber, sells logs and leases land for hunting and other recreational activity. The Real Estate Division develops and sells land parcels, as well as invests in timberlands. The Wood Products Division manufactures lumber, plywood, and particleboard in Arkansas, Idaho, Michigan, and Minnesota. This segment’s products are sold to wholesalers primarily for use in home building and other construction activities. Potlatch was founded in 1903 and is headquartered in Spokane, Washington.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Comerica Bank lifted its stake in shares of Potlatchdeltic Corp (NASDAQ:PCH) by 9.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,810 shares of the real estate investment trust’s stock after purchasing an additional 3,890 shares during the quarter. Comerica Bank owned about 0.07% of Potlatchdeltic worth $1,676,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Potlatchdeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit

Best Insurance Stocks To Invest In 2023: Graco Inc.(GGG)

Graco Inc., together with its subsidiaries (“Graco,” “us,” “we,” or “our Company”), is a multi-national manufacturing company. We design, manufacture and market equipment used to pump, meter, mix and dispense fluid and powder materials. Our equipment is used in construction, automotive, mining, oil and natural gas, process, public works and other industries. Graco is a Minnesota corporation and was incorporated in 1926.
We specialize in providing equipment solutions for difficult-to-handle materials with high viscosities, abrasive or corrosive properties, and multiple component materials that require precise ratio control. We aim to serve niche markets, providing high customer value through product differentiation. Our products enable customers to reduce their use of labor, material and energy, improve quality and achieve environmental compliance.
We make significant investments in developing innovative, high quality products.   Advisors’ Opinion:

  • [By Joseph Griffin]

    Graco Inc. (NYSE:GGG) – Analysts at William Blair lowered their Q1 2019 earnings per share (EPS) estimates for Graco in a research report issued to clients and investors on Tuesday, January 29th. William Blair analyst N. Heymann now forecasts that the industrial products company will post earnings per share of $0.49 for the quarter, down from their previous forecast of $0.51. William Blair also issued estimates for Graco’s Q4 2019 earnings at $0.44 EPS and FY2020 earnings at $2.18 EPS.

  • [By Shane Hupp]

    Zacks Investment Management acquired a new stake in Graco Inc. (NYSE:GGG) in the second quarter, reports. The fund acquired 5,096 shares of the industrial products company’s stock, valued at approximately $230,000.

  • [By Logan Wallace]

    Shares of Graco Inc. (NYSE:GGG) have been given a consensus rating of “Hold” by the eleven brokerages that are currently covering the firm, reports. Nine research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $49.17.

  • [By Shane Hupp]

    Shares of Graco Inc. (NYSE:GGG) have been assigned an average recommendation of “Hold” from the twelve brokerages that are covering the stock, reports. Ten equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $49.04.

Best Insurance Stocks To Invest In 2023: Cassava Sciences, Inc.(SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Advisors’ Opinion:

  • [By Louis Navellier and the InvestorPlace Research Staff]

    Since biotechnology company Cassava Sciences (NASDAQ:SAVA) is working hard to fight Alzheimer’s disease, it might be surprising to know that the company has some harsh critics. There’s a lot of drama going on with Cassava, and SAVA stock traders need to be aware of the latest developments.

  • [By Larry Ramer]

    Allegations of fraud against Cassava Sciences (NASDAQ:SAVA) are unlikely to stop its Alzheimer’s drug candidate from quickly advancing to a Phase 3 clinical trial. As a result, I remain very bullish on SAVA stock.

  • [By ]

    Cassava Sciences  (SAVA) – Get Cassava Sciences, Inc. Report tumbled Friday after the drugmaker's CEO issued a statement rebutting recent allegations against the quality of testing for the company's Alzheimer's disease treatment and was attacked on social media.

Leave a Reply

Your email address will not be published.